KCNB1 and early-onset autosomal dominant Alzheimer disease: It is therefore to be hoped that in the future, some of the drugs that target components of the integrin-α5-KCNB1 complexes signaling machinery could be repurposed for the treatment of diseases, including Alzheimer’s disease, TBI, and stroke.